Trial · NCT07896187
A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
NCT07896187, Phase 1, Not yet recruiting, Nuwacell Biotechnologies Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS. Trials, record NCT07896187. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896187
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
- NCT number
- NCT07896187
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Conditions
- PARKINSON DISEASE (Disorder), Cell Therapy, Human Induced Pluripotent Stem Cells, Deep Brain Stimulation, Phase 1 Clinical Trial, Dopaminergic Progenitor Cells
- Interventions
- NCR201
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Adverse Events | From the time of cell infusion up to 12 months after NCR201 transplantation | To evaluate the safety and tolerability of stereotactic intracerebral injection of NCR201 by assessing the type, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs). |
| Primary | Maximum Tolerated Dose (MTD) of NCR201 | Within 12 months after NCR201 transplantation | Change from baseline in UPDRS Part III motor score to evaluate motor function improvement following NCR201 cell injection. |
| Secondary | Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score | Baseline, 3 months, 6 months and 12 months after NCR201 transplantation | Change from baseline in UPDRS Part III motor score to evaluate motor function improvement following NCR201 cell injection. |
| Secondary | Survival and engraftment of grafted cells assessed by brain PET/MRI imaging | Baseline, 6 months and 12 months after NCR201 transplantation | Brain PET and MRI imaging to evaluate the survival, location and engraftment of transplanted NCR201 dopaminergic progenitor cells in the putamen. |
| Secondary | Change in UPDRS Part II Activities of Daily Living Score | Baseline, 3 months, 6 months and 12 months after NCR201 transplantation | Change from baseline in UPDRS Part II score to assess activities of daily living in Parkinson's subjects after NCR201 treatment. |
| Secondary | Change in levodopa equivalent daily dose (LEDD) | Baseline, 3 months, 6 months and 12 months after NCR201 transplantation | Change from baseline in levodopa equivalent daily dose (LEDD) to assess reduction of anti-parkinson medication requirement. |
| Secondary | Change in UPDRS Part I Non-motor Experiences of Daily Living Score | Baseline, 3 months, 6 months and 12 months after NCR201 transplantation | Change from baseline in UPDRS Part I score to evaluate non-motor symptoms in Parkinson's patients receiving NCR201. |
| Secondary | Incidence of anti-NCR201 alloantibody formation | Baseline, 1 month, 3 months, 6 months and 12 months after NCR201 transplantation | Detection of anti-donor alloantibodies in peripheral blood to assess immune response against transplanted NCR201 cells. |
| Secondary | Change in Parkinson's Disease Questionnaire (PDQ-39) quality of life score | Baseline, 6 months and 12 months after NCR201 transplantation | Change from baseline in PDQ-39 total score to evaluate health-related quality of life after NCR201 cell transplantation. |
| Secondary | Change in dyskinesia rating scale score | Baseline, 3 months, 6 months and 12 months after NCR201 transplantation | Change from baseline in dyskinesia rating scale to assess the severity of levodopa-induced dyskinesia. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896187
GET https://conductscience.org/api/trials/v1/NCT07896187/registered